New start-up Quench Bio works on novel immunotherapy approach

Venture capital firm Arix Bioscience has founded a new biotech, Quench Bio, aimed at developing candidates which inhibit the protein Gasdermin D, a target at the core of multiple inflammatory cell death pathways.

The company, which is starting out with a series A financing round of about $50 million, has been co-founded and seeded by both Arix and Atlas Venture.

The science behind the therapeutic approach originates from Arix’s long-standing relationship with the Lead Discovery Center in Germany and the Max Planck Society.